优游国际

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2024

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNOVATIVE DRUG BENMELSTOBART INJECTION "BENMELSTOBART (TQB2450)" IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR THE INDICATION OF FIRST-LINE TREATMENT FOR SMALL CELL LUNG CANCER

IMPLEMENTATION OF SHARE INCENTIVE SCHEME BY CHIA TAI TIANQING

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNVOATIVE DRUG UNECRITNIB FUMARATE CAPSULES "UNECRITINIB (TQ-B3101)"

FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING (OR ANY ADJOURNMENT THEREOF)